Exploring new antibacterial agents called ozonides
Defining the antibacterial activities of ozonides
['FUNDING_R03'] · MICHIGAN STATE UNIVERSITY · NIH-11042251
This study is looking at a new type of medicine called ozonides to see if they can help fight tough bacterial infections, especially those that don't respond to regular antibiotics, like tuberculosis, so that patients can have better treatment options.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MICHIGAN STATE UNIVERSITY (nih funded) |
| Locations | 1 site (EAST LANSING, UNITED STATES) |
| Trial ID | NIH-11042251 on ClinicalTrials.gov |
What this research studies
This research investigates the potential of ozonides, a new class of synthetic peroxides, to combat bacterial infections, particularly those resistant to existing antibiotics. The study focuses on their effectiveness against various bacterial pathogens, including Mycobacterium tuberculosis, which is known for its resistance to many treatments. By analyzing the antibacterial properties and safety of ozonides, the research aims to develop novel therapies that could be used to treat infections that currently have limited treatment options. Patients may benefit from new medications that are effective against resistant bacteria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria, particularly those with tuberculosis.
Not a fit: Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat infections caused by drug-resistant bacteria.
How similar studies have performed: While the use of ozonides as antibacterials is a novel approach, there is ongoing research into their effectiveness as antimalarials, suggesting potential for success in antibacterial applications.
Where this research is happening
EAST LANSING, UNITED STATES
- MICHIGAN STATE UNIVERSITY — EAST LANSING, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABRAMOVITCH, ROBERT B — MICHIGAN STATE UNIVERSITY
- Study coordinator: ABRAMOVITCH, ROBERT B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.